Skip to main content

Advertisement

SpringerLink
Log in

Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Vasohibin-1(VASH1) has recently been isolated as a novel negative feedback inhibitor of angiogenesis. Several studies have demonstrated that VASH1 plays important roles in tumor angiogenesis but the role of this angiogenic inhibitor in renal cell carcinoma (RCC) has not been elucidated until now. In this study, we investigated the expression pattern of VASH1 and the association with clinicopathological features in RCC. Expression of VASH1, hypoxia-inducible factor-1α (HIF-1α), and microvessel density (MVD, labeled by CD34) was assessed by immunohistochemistry in 46 RCC specimens and 20 adjacent nontumorous renal tissues (ANRTs). Correlation between vasohibin-1 and HIF-1α, MVD, and clinicopathological features was then investigated. In RCC, VASH1 was expressed mainly in the cytoplasm and membrane of tumor cells and partly in vascular endothelial cells. In ANRT, it was mainly expressed in the cytoplasm and membrane of renal tubular epithelial cells and partly in vascular endothelial cells and glomerular mesangial cells. The expression level of VASH1 in RCC tissue was significantly lower than that in ANRT and was significantly reduced with the increased degree of malignancy in RCC tissues. In addition, a significantly negative correlation was noted between VASH1 expression and HIF-1α expression and a significantly negative correlation was noted between VASH1 expression and MVD in RCC. Therefore, VASH1 expression is reduced and it associates with clinicopathological features in RCC. Based on our findings and the knowledge of other angiogenesis inhibitors, we postulate that VASH1 would potentially be a biomarker and a candidate for molecular targeted therapy for patients with RCC in the future.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009;373:1119–32.

    Article  PubMed  CAS  Google Scholar 

  2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–75.

    Article  PubMed  CAS  Google Scholar 

  3. Ljungberg B, Campbell SC, Cho HY, Jacqmin D, Lee JE, Weikert S, et al. The epidemiology of renal cell carcinoma. Eur Urol Eur Urol. 2011;60(4):615–21.

    Google Scholar 

  4. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–6.

    Article  PubMed  CAS  Google Scholar 

  5. Folkman J, Kerbel R. Role of angiogenesis in tumor growth and metastasis Clinical translation of angiogenesis inhibitors. Semin Oncol. 2002;29:15–8.

    PubMed  CAS  Google Scholar 

  6. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249–57.

    Article  PubMed  CAS  Google Scholar 

  7. Qian CN, Huang D, Wondergem B, Teh BT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer. 2009;115:2282–9.

    Article  PubMed  CAS  Google Scholar 

  8. Xu L, Tong R, Cochran DM, Jain RK. Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model. Cancer Res. 2005;65:5711–9.

    Article  PubMed  CAS  Google Scholar 

  9. Sulzbacher I, Birner P, Traxler M, Marberger M, Haitel A. Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma. Am J Clin Pathol. 2003;120:107–12.

    Article  PubMed  CAS  Google Scholar 

  10. Dorević G, Matusan-Ilijas K, Babarović E, et al. Hypoxia inducible factor-1α correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2009;28:40.

    Article  PubMed  Google Scholar 

  11. Watanabe K, Hasegawa Y, Yamashita H, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 2004;114:898–907.

    PubMed  CAS  Google Scholar 

  12. Sonoda H, Ohta H, Watanabe K, et al. Multiple processing forms and their biological activities of a novel angiogenesis inhibitor vasohibin. Biochem Biophys Res Commun. 2006;342:640–6.

    Article  PubMed  CAS  Google Scholar 

  13. Nasu T, Maeshima Y, Kinomura M, et al. Vasohibin-1, a negative feedback regulator of angiogenesis, ameliorates renal alterations in a mouse model of diabetic nephropathy. Diabetes. 2009;58:2365–75.

    Article  PubMed  CAS  Google Scholar 

  14. Shen J, Yang X, Xiao WH, et al. Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J. 2006;20:723–5.

    PubMed  CAS  Google Scholar 

  15. Tamaki K, Moriya T, Sato Y, et al. Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci. 2009;100:88–94.

    Article  PubMed  CAS  Google Scholar 

  16. Yoshinaga K, Ito K, Moriya T, et al. Expression of vasohibin as a novel endothelium-derived angiogenesis inhibitor in endometrial cancer. Cancer Sci. 2008;99:914–9.

    Article  PubMed  CAS  Google Scholar 

  17. Yoshinaga K, Ito K, Moriya T, et al. Roles of intrinsic angiogenesis inhibitor, vasohibin, in cervical carcinomas. Cancer Sci. 2011;102:446–51.

    Article  PubMed  CAS  Google Scholar 

  18. Hosaka T, Kimura H, Heishi T, et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol. 2009;175:430–9.

    Article  PubMed  Google Scholar 

  19. Wang Q, Tian X, Zhang C, et al. Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol. 2011. doi:10.1007/s12032-011-0106-7.

  20. Shen Z, Kauttu T, Seppänen H, et al. Vasohibin-1 and vasohibin-2 expression in gastric cancer cells and TAMs. Med Oncol. 2012;. doi:10.1007/s12032-012-0212-1.

    Google Scholar 

  21. Eble JN, Sauter G, Epstein JI, et al. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARC; 2004. p. 12–43.

    Google Scholar 

  22. Störkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma. Cancer. 1997;80:987–9.

    Article  PubMed  Google Scholar 

  23. Edge SB, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York: Springer; 2009. p. 547–60.

    Google Scholar 

  24. Mancilla JR, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer. 1976;38:2469–80.

    Article  Google Scholar 

  25. Shimizu K, Watanabe K, Yamashita H, et al. Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. Biochem Biophys Res Commun. 2005;327:700–6.

    Article  PubMed  CAS  Google Scholar 

  26. Nimmagadda S, Geetha-Loganathan P, Pröls F, et al. Expression pattern of vasohibin during chick development. Dev Dyn. 2007;236:1358–62.

    Article  PubMed  CAS  Google Scholar 

  27. Naito H, Kidoya H, Sato Y, et al. Induction and expression of anti-angiogenic vasohibins in the hematopoietic stem/progenitor cell population. J Biochem. 2009;145:653–9.

    Article  PubMed  CAS  Google Scholar 

  28. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007;26:225–39.

    Article  PubMed  CAS  Google Scholar 

  29. Pantuck AJ, Zeng G, Belldegrun AS, et al. Pathobiology, prognosis and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res. 2003;9:4641–52.

    PubMed  CAS  Google Scholar 

  30. Marcella M. van Vlodrop IJH, Vermeulen PB, et al. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221:125–38.

    Article  Google Scholar 

  31. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999;56:794–814.

    Article  PubMed  CAS  Google Scholar 

  32. Jacobsen J, Grankvist K, Rasmuson T, et al. Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int. 2004;93(3):297–302.

    Article  PubMed  CAS  Google Scholar 

  33. Lidgren A, Hedberg Y, Grankvist K. ea al. Hypoxia-inducible factor 1a expression in renal cell carcinoma analyzed by tissue microarray. Eur Urol. 2006;50:1272–7.

    Article  PubMed  CAS  Google Scholar 

  34. Lidgren A, Hedberg Y, Grankvist K, et al. The expression of hypoxia-inducible factor 1alpha is a favorable independent prognostic factor in renal cell carcinoma. Clin Cancer Res. 2005;11:1129–35.

    PubMed  CAS  Google Scholar 

  35. Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36:169–80.

    Article  PubMed  CAS  Google Scholar 

  36. Delahunt B, Bethwaite PB, Thornton A. Prognostic significance of microscopic vascularity for clear cell renal cell carcinoma. Br J Urol. 1997;80:401–4.

    Article  PubMed  CAS  Google Scholar 

  37. Yildiz E, Ayan S, Goze F, et al. Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma. BJU Int. 2008;101(6):758–64.

    Article  PubMed  Google Scholar 

  38. Dekel Y, Koren R, Kugel V, et al. Significance of angiogenesis and microvascular invasion in renal cell carcinoma. Pathol Oncol Res. 2002;8:129–32.

    Article  PubMed  Google Scholar 

  39. Joo HJ, Oh DK, Kim YS, et al. Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int. 2004;93(3):291–6.

    Article  PubMed  CAS  Google Scholar 

  40. Suzuki K, Morita T, Hashimoto S, Tokue A. Thymidine phosphorylase/platelet-derived cell growth factor (PD-ECGF) associated with prognosis in renal cell carcinoma. Urol Res. 2001;29:7–12.

    Article  PubMed  CAS  Google Scholar 

  41. Slaton JW, Inoue K, Perrotte P, et al. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am J Pathol. 2001;158:735–43.

    Article  PubMed  CAS  Google Scholar 

  42. Miyashita H, Suzuki H, Ohkuchi A, et al. Mutual balance between vasohibin-1 and soluble VEGFR-1 in endothelial cells. Pharmaceuticals. 2011;4:782–93.

    Article  CAS  Google Scholar 

  43. Wakusawa R, Abe T, Sato H, et al. Suppression of choroidal neovascularization by vasohibin-1, a vascular endothelium–derived angiogenic inhibitor. Invest Ophthalmol Vis Sci. 2011;52:3272–80.

    Article  PubMed  CAS  Google Scholar 

  44. Kozako T, Matsumoto N, Kuramoto Y, et al. Vasohibin induces prolyl hydroxylase-mediated degradation of hypoxia-inducible factor-1a in human umbilical vein endothelial cells. FEBS Lett. 2012;586:1067–72.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interests

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Tianjin Institute of Urology, Department of Urology, Second Hospital of Tianjin Medical University, no 23, Pingjiang Road, Hexi District, Tianjin, China

    Guangning Zhao, Yuming Yang, Yang Tang, Ruifa Han & Yan Sun

Authors
  1. Guangning Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yuming Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yang Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruifa Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Ruifa Han or Yan Sun.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhao, G., Yang, Y., Tang, Y. et al. Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma. Med Oncol 29, 3325–3334 (2012). https://doi.org/10.1007/s12032-012-0313-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-012-0313-x

Keywords

Search

Navigation